NUCLIDIUM closes Series B for € 84 million

Basel, Switz­er­land / Munich, Germany — NUCLIDIUM, a clini­­cal-stage radio­phar­maceu­ti­cal company deve­lo­ping a proprie­tary copper-based ther­ano­stic plat­form, announ­ced the closing of its Series B finan­cing round of CHF 79 million (EUR 84 million). The round was led by Kurma Growth Oppor­tu­ni­ties Fund, Ange­lini Ventures, Welling­ton Part­ners and Neva SGR (Intesa Sanpaolo Group), with parti­ci­pa­tion from DeepT­ech & Climate Fonds (DTCF), Bayern Kapi­tal, Vives Part­ners, Eura­zeo, NRW.BANK and High­Light Capi­tal, as well as exis­ting investors. 

The proceeds will be used to advance the clini­cal deve­lo­p­ment of NUCLI­DI­UM’s copper-61/cop­­per-67 (61Cu/67Cu) ther­ano­stic pipe­line in various onco­logy indi­ca­ti­ons. In paral­lel, the company will expand its produc­tion and manu­fac­tu­ring capa­bi­li­ties through a global manu­fac­tu­ring network. 

NUCLI­DI­UM’s diffe­ren­tia­ted plat­form combi­nes tumor-targe­­ting mole­cu­les with copper isoto­pes — copper-61 for diagno­stics and copper-67 for therapy — to over­come current limi­ta­ti­ons in radio­ther­ano­stics, such as subop­ti­mal clini­cal effi­cacy and manu­fac­tu­ring comple­xity. Diagno­stic results from initial clini­cal studies in these indi­ca­ti­ons show better lesion detec­tion and tumor-to-back­­ground ratios compared to clini­cally appro­ved tracers. Initial data was recently presen­ted at SNMMI 2025 by Dr. Gary Ulaner, MD, PhD, demons­t­ra­ting a favorable safety profile and poten­ti­ally impro­ved imaging perfor­mance of 61Cu-Nuri­­Pro™ compared to current PET imaging stan­dards, suggest­ing great clini­cal poten­tial and broa­der poten­tial for the ther­ano­stic pairing of 61Cu/67Cu. Early thera­peu­tic data from the two lead compounds Nuri­Pro™ and Trace­NET™ show good tumor-to-back­­ground ratios in meta­sta­tic prostate cancer and neuro­en­do­crine tumors, inclu­ding breast cancer. 

“NUCLIDIUM is ente­ring the next clini­cal phases with its compounds for the diagno­sis and treat­ment of meta­sta­tic prostate cancer, neuro­en­do­crine tumors and breast cancer,” said Leila Jaafar, PhD, CEO and co-foun­­der of NUCLIDIUM. “Our copper-based radio­ther­ano­stics are desi­gned for seam­less use in hospi­tal work­flows, care and waste manage­ment, making these thera­pies more acces­si­ble worldwide.” 

With this finan­cing, NUCLIDIUM will further expand its global produc­tion and manu­fac­tu­ring network for diagno­stics and thera­peu­tics, grow its inter­na­tio­nal team and streng­then its stra­te­gic colla­bo­ra­tion with hospi­tals and acade­mic centers, initi­ally in Europe and North America.

In connec­tion with the finan­cing round, Dr. Daniel Parera, Part­ner at Kurma Part­ners, Dr. Regina Hodits, Mana­ging Direc­tor at Ange­lini Ventures, and Liliana Nord­bakk, Life Scien­ces Part­ner at Neva SGR, will join the Board of Direc­tors of NUCLIDIUM.

Consul­tant NUCLIDIUM:

The Series B finan­cing was supported by VISCHER AG and Walder Wyss, Switz­er­land, as legal advisors.

About NUCLIDIUM

NUCLIDIUM AG is a clini­­cal-stage biotech­no­logy company pionee­ring the deve­lo­p­ment of next-gene­ra­­tion copper-based radio­phar­maceu­ti­cals for the diagno­sis and treat­ment of cancer. Through the use of copper isoto­pes — copper-61 for diagno­stics and copper-67 for therapy — NUCLIDIUM is crea­ting a diffe­ren­tia­ted plat­form that has the poten­tial to over­come exis­ting limi­ta­ti­ons in radiotheranostics. 

The company’s opera­ti­ons in Switz­er­land and Germany combine inno­va­tive chemis­try, deep clini­cal exper­tise and stra­te­gic manu­fac­tu­ring capa­bi­li­ties to provide scalable, acces­si­ble and clini­cally supe­rior ther­ano­stic solu­ti­ons to pati­ents world­wide. NUCLI­DI­UM’s mission is to increase the reach and effi­cacy of radio­ther­ano­stics while addres­sing criti­cal unmet medi­cal needs in onco­logy and women’s health.

Home